Study Demographics
| Characteristic | Data |
| Median age (y) | 65 (range, 42–91) |
| Gleason grade at initial diagnosis (n) | |
| 6 | 7 (25%) |
| 7–8 | 11 (39%) |
| 9–10 | 9 (32%) |
| Not available | 1 (4%) |
| Prior prostate cancer therapy (n) | |
| None | 4 (14%) |
| Radical prostatectomy | 12 (43%) |
| Brachytherapy | 1 (4%) |
| Radiation | 11 (39%) |
| ADT | 19 (68%) |
| Chemotherapy | 6 (21%) |
| 223Ra | 1 (4%) |
| Castration status (n) | |
| Untreated | 3 (11%) |
| Castrate-sensitive | 14 (50%) |
| Castrate-resistant | 11 (39%) |
| Median PSA at baseline (ng/mL) | 2.08 (range, 0.07–4,379) |
| Therapy at baseline (n) | |
| No treatment | 9 (32%) |
| ADT | 16 (57%) |
| ADT + other | 3 (11%) |
| Median PSA at follow-up (ng/mL) | 0.76 (0.02–1,046) |
| Therapy in scan interval (n) | |
| No treatment | 3 (13%) |
| ADT | 14 (61%) |
| ADT + other | 6 (26%) |
| Baseline imaging (n) | |
| NaF PET/CT | 28 (100%) |
| DCFBC (1 h) PET/CT | 28 (100%) |
| DCFBC (2 h) PET/CT | 27 (96%) |
| Follow-up imaging (n) | |
| NaF PET/CT | 23 (100%) |
| DCFBC (1 h) PET/CT | 22 (96%) |
| DCFBC (2 h) PET/CT | 23 (100%) |